AR067413A1 - Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer - Google Patents
Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancerInfo
- Publication number
- AR067413A1 AR067413A1 ARP080102885A ARP080102885A AR067413A1 AR 067413 A1 AR067413 A1 AR 067413A1 AR P080102885 A ARP080102885 A AR P080102885A AR P080102885 A ARP080102885 A AR P080102885A AR 067413 A1 AR067413 A1 AR 067413A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- membered
- troliferative
- tiperiferative
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- LTFBFZBWUKWXID-UHFFFAOYSA-N 1h-cyclopenta[d]pyrimidine Chemical compound N1=CNC2=CC=CC2=C1 LTFBFZBWUKWXID-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 abstract 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 abstract 2
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- QUYPSOKUBYENRV-UHFFFAOYSA-N 1h-pyrazole;pyridine Chemical compound C=1C=NNC=1.C1=CC=NC=C1 QUYPSOKUBYENRV-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Reivindicacion 1: Un compuesto de la formula (1) y sus enantiomeros y sales, donde: G es fenilo, naftaleno, un heteroarilo de 5-6 miembros o un heteroarilo bicíclico de 9-10 miembros, donde el fenilo, naftaleno, o heteroarilo de 5-6 miembros o heteroarilo bicíclico de 9-10 miembros están opcionalmente sustituidos con uno a cuatro grupos Ra; R1 y R1a se seleccionan, de manera independiente, de H, Me, Et, -CH=CH2, -CH2OH, CF3, CHF2 o CH2F; R2 es H, -OH, -OMe o F; R2a es H, Me o F, o R2 y R2a son oxo; R3es H, Me, Et, o CF3; R4 es H, heterociclo de 4-6 miembros, ciclopropilmetilo o alquilo C1-4 opcionalmente sustituido con F, -OH o -Oalquilo C1-3; R5 y R5a se seleccionan, de manera independiente, de H y alquilo C1-4; o R5 y R5a junto con el átomo al cual están unidos forman un grupo carbonilo, un cicloalquilo de 5-6 miembros o un heterociclo de 5-6 miembros, donde el heterociclo tiene un heteroátomo de oxigeno; cada Ra es, de manera independiente, halogeno, alquilo C1-6, cicloalquilo C3-6, -O-alquilo C1-6, CF3, -OCF3, Salquilo C1-6, CN, fenilo, -OCH2-fenilo, NH2, -NO2, -NH-alquilo C1-6, -N-(alquilo C1-6)2, piperidina, pirrolidina, pirazol piridina, 2-aminopiridina, CH2F, CHF2, -OCH2F, -OCHF2, -OH, -SO2alquilo C1-6, C(O)NH2, C(O)NHalquilo C1-6 y C(O)N(alquilo C1-6)2 y j es 1 o 2; y cuando j es 2, el carbono de anillo de j opuesto a NR4 puede ser reemplazado con un heteroátomo O.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94813807P | 2007-07-05 | 2007-07-05 | |
| US2008808P | 2008-01-09 | 2008-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067413A1 true AR067413A1 (es) | 2009-10-07 |
Family
ID=40076864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102885A AR067413A1 (es) | 2007-07-05 | 2008-07-03 | Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8618097B2 (es) |
| EP (1) | EP2170863B1 (es) |
| JP (2) | JP5628028B2 (es) |
| KR (2) | KR20150089099A (es) |
| CN (2) | CN103396409B (es) |
| AR (1) | AR067413A1 (es) |
| AU (1) | AU2008272830B8 (es) |
| BR (1) | BRPI0813999A2 (es) |
| CA (1) | CA2692502C (es) |
| CO (1) | CO6251283A2 (es) |
| CR (1) | CR11229A (es) |
| EC (1) | ECSP109937A (es) |
| ES (1) | ES2551352T3 (es) |
| MA (1) | MA31679B1 (es) |
| NZ (1) | NZ582692A (es) |
| RU (1) | RU2486181C2 (es) |
| SG (1) | SG185274A1 (es) |
| TW (1) | TWI450720B (es) |
| WO (1) | WO2009006567A2 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2068878B1 (en) | 2006-09-20 | 2019-04-10 | Aerie Pharmaceuticals, Inc. | Rho kinase inhibitors |
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| WO2009089352A1 (en) | 2008-01-08 | 2009-07-16 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
| EP2240455B1 (en) | 2008-01-09 | 2012-12-26 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor |
| EP2240483B8 (en) * | 2008-01-09 | 2013-04-03 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| ES2422733T3 (es) | 2008-01-09 | 2013-09-13 | Array Biopharma Inc | Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT |
| US8372842B2 (en) | 2008-01-09 | 2013-02-12 | Array Biopharma Inc. | Pyrazolopyridines as kinase inhibitors |
| ES2426092T3 (es) | 2008-01-09 | 2013-10-21 | Array Biopharma, Inc. | 5H-Ciclopenta[d]pirimidinas como inhibidores de proteínas cinasas AKT |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| ES2834451T3 (es) | 2009-05-01 | 2021-06-17 | Aerie Pharmaceuticals Inc | Inhibidores de mecanismo doble para el tratamiento de enfermedades |
| JP2013528787A (ja) | 2010-04-16 | 2013-07-11 | ジェネンテック， インコーポレイテッド | Ｐｉ３ｋ／ａｋｔキナーゼ経路インヒビターの効果の予測バイオマーカーとしてのｆｏｘ０３ａ |
| SG10201507582VA (en) | 2011-04-01 | 2015-10-29 | Genentech Inc | Biomarkers for predicting sensitivity to cancer treatments |
| KR102678074B1 (ko) | 2012-05-17 | 2024-06-26 | 제넨테크, 인크. | 무정형 형태의 akt 저해성 피리미디닐 - 사이클로펜탄 화합물, 조성물 및 이들의 방법 |
| US9452990B2 (en) | 2012-06-20 | 2016-09-27 | Novartis Ag | Complement pathway modulators and uses thereof |
| KR102182488B1 (ko) | 2013-02-25 | 2020-11-24 | 제넨테크, 인크. | 약물 내성 akt 돌연변이체의 검출 및 치료를 위한 방법 및 조성물 |
| PT3811943T (pt) | 2013-03-15 | 2023-03-15 | Aerie Pharmaceuticals Inc | Composto para uso no tratamento de distúrbios oculares |
| US10550087B2 (en) | 2015-11-17 | 2020-02-04 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| US11389441B2 (en) | 2016-08-31 | 2022-07-19 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
| CA3041840A1 (en) | 2016-10-28 | 2018-05-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating ezh2-mediated cancer |
| JP2020515583A (ja) | 2017-03-31 | 2020-05-28 | アエリエ ファーマシューティカルズ インコーポレイテッド | アリールシクロプロピル−アミノ−イソキノリニルアミド化合物 |
| US11472799B2 (en) * | 2018-03-06 | 2022-10-18 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use |
| JP7720698B2 (ja) * | 2018-04-04 | 2025-08-08 | アルビナス・オペレーションズ・インコーポレイテッド | タンパク質分解の調節因子および関連する使用方法 |
| CA3104298A1 (en) | 2018-06-21 | 2019-12-26 | Icahn School Of Medicine At Mount Sinai | Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use |
| AU2019337703B2 (en) | 2018-09-14 | 2023-02-02 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| US20220185796A1 (en) * | 2019-03-27 | 2022-06-16 | St. Jude Children's Research Hospital | Small molecule modulators of pank |
| CN114423463B (zh) | 2019-05-06 | 2025-09-26 | 西奈山伊坎医学院 | 作为hpk1的降解剂的异双功能化合物 |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| CN117677614A (zh) * | 2021-12-17 | 2024-03-08 | 中国医药研究开发中心有限公司 | 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途 |
| KR20250151412A (ko) | 2023-01-26 | 2025-10-21 | 아비나스 오퍼레이션스, 인코포레이티드 | 세레블론계 kras 분해 단백질 및 이와 관련된 용도 |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3885035A (en) | 1972-04-05 | 1975-05-20 | Sandoz Ag | Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines |
| US3956495A (en) | 1973-10-30 | 1976-05-11 | Eli Lilly And Company | 2,4-Diaminoquinazolines as antithrombotic agents |
| US3966936A (en) | 1974-02-21 | 1976-06-29 | Pfizer Inc. | Piperazino quinazoline bronchodilators |
| US4060615A (en) | 1976-02-18 | 1977-11-29 | Mead Johnson & Company | 2-Piperazinyl-6,7-dimethoxyquinazolines |
| JPS562968A (en) | 1979-06-21 | 1981-01-13 | Mitsubishi Yuka Yakuhin Kk | Novel pyrimidine derivative |
| US4749704A (en) | 1985-03-07 | 1988-06-07 | Sankyo Company Limited | Cyclopenta[d]pyrimidine derivatives and use as antidepressants |
| MX19185A (es) | 1989-01-20 | 1993-12-01 | Pfizer | Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas. |
| WO1994007890A1 (fr) | 1992-10-05 | 1994-04-14 | Ube Industries, Ltd. | Compose pyrimidine |
| WO1995003286A1 (en) | 1993-07-23 | 1995-02-02 | The Green Cross Corporation | Triazole derivative and pharmaceutical use thereof |
| GB9416189D0 (en) | 1994-08-10 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
| JP2896532B2 (ja) | 1994-08-13 | 1999-05-31 | ユーハン コーポレーション | 新規なピリミジン誘導体およびその製造方法 |
| US5525625A (en) | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
| US7067664B1 (en) | 1995-06-06 | 2006-06-27 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| ZA979961B (en) | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6821963B2 (en) | 1997-07-01 | 2004-11-23 | Warner-Lambert Company | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
| AU756586C (en) | 1997-07-01 | 2004-01-29 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| ES2229515T3 (es) | 1997-07-01 | 2005-04-16 | Warner-Lambert Company Llc | Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek. |
| US6506798B1 (en) | 1997-07-01 | 2003-01-14 | Warner-Lambert Company | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors |
| US6310060B1 (en) | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| ES2356886T3 (es) | 1998-03-31 | 2011-04-14 | Kyowa Hakko Kirin Co., Ltd. | Compuestos heterocíclicos nitrogenados. |
| DE19853278A1 (de) | 1998-11-19 | 2000-05-25 | Aventis Pharma Gmbh | Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| ATE292462T1 (de) | 1999-01-07 | 2005-04-15 | Warner Lambert Co | Behandlung von asthma anhand von mek-inhibitoren |
| EP1140067A1 (en) | 1999-01-07 | 2001-10-10 | Warner-Lambert Company | Antiviral method using mek inhibitors |
| WO2000042002A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
| US6545030B1 (en) | 1999-01-13 | 2003-04-08 | Warner-Lambert Company | 1-heterocycle substituted diarylamines |
| JP2002534446A (ja) | 1999-01-13 | 2002-10-15 | ワーナー−ランバート・カンパニー | ４′ヘテロアリールジアリールアミン |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| IL144214A0 (en) | 1999-01-13 | 2002-05-23 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors |
| US6440966B1 (en) | 1999-01-13 | 2002-08-27 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as MEK inhibitors |
| GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| HK1047895A1 (zh) | 1999-07-16 | 2003-03-14 | 沃尼尔‧朗伯公司 | 使用mek抑制剂治疗慢性疼痛的方法 |
| CA2377100A1 (en) | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
| TR200200082T2 (tr) | 1999-07-16 | 2002-04-22 | Warner-Lambert Company | MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi. |
| CN1358094A (zh) | 1999-07-16 | 2002-07-10 | 沃尼尔·朗伯公司 | 用mek抑制剂治疗慢性疼痛的方法 |
| AU2001247372A1 (en) | 2000-03-15 | 2001-09-24 | Warner Lambert Company | 5-amide substituted diarylamines as mex inhibitors |
| DZ3401A1 (fr) | 2000-07-19 | 2002-01-24 | Warner Lambert Co | Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques |
| IL154507A0 (en) | 2000-08-25 | 2003-09-17 | Warner Lambert Co | Process for making n-aryl-anthranilic acids and their derivatives |
| ATE346064T1 (de) | 2000-09-15 | 2006-12-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinasehemmer |
| EP1337524A1 (en) | 2000-11-02 | 2003-08-27 | AstraZeneca AB | Substituted quinolines as antitumor agents |
| WO2002083139A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
| CA2446514A1 (en) | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) |
| WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| TWI338685B (en) | 2002-03-13 | 2011-03-11 | Array Biopharma Inc | N3 alkylated benzimid azole derivatives as mek inhibitors |
| PA8569201A1 (es) | 2002-03-13 | 2004-05-21 | Array Biopharma Inc | "derivados de bencimidazol n3 alquilado como inhibidores de mek" "n3 alkylated benzimimidazole derivatives as mek inhibitors" |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| CA2480880C (en) | 2002-04-08 | 2011-03-22 | Merck & Co., Inc. | Inhibitors of akt activity |
| JP4394959B2 (ja) | 2002-04-08 | 2010-01-06 | メルク エンド カムパニー インコーポレーテッド | Ａｋｔ活性の阻害剤 |
| CA2481241C (en) | 2002-04-08 | 2010-07-27 | Merck & Co., Inc. | Fused quinoxaline derivatives as inhibitors of akt activity |
| WO2003086394A1 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
| EP1503761A1 (en) | 2002-05-10 | 2005-02-09 | Neurocrine Biosciences, Inc. | Substituted piperazines as melanocortin receptor ligands |
| AU2003284981B2 (en) | 2002-10-30 | 2009-05-28 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| US20040102360A1 (en) | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| CN1809351A (zh) | 2003-04-24 | 2006-07-26 | 麦克公司 | Akt活性抑制剂 |
| ATE440825T1 (de) | 2003-06-06 | 2009-09-15 | Vertex Pharma | Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern |
| EP1663994B1 (en) | 2003-08-05 | 2012-03-07 | Vertex Pharmaceuticals Incorporated | Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels |
| JP2007501821A (ja) | 2003-08-12 | 2007-02-01 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｆｒアンタゴニストとしてのテトラヒドロキナゾリン誘導体 |
| EP1666468A4 (en) | 2003-09-09 | 2007-03-21 | Ono Pharmaceutical Co | CRF ANTAGONISTS AND HETEROBICYCLIC COMPOUNDS |
| US20050182061A1 (en) | 2003-10-02 | 2005-08-18 | Jeremy Green | Phthalimide compounds useful as protein kinase inhibitors |
| PH12012501891A1 (en) | 2003-11-21 | 2013-09-02 | Array Biopharma Inc | Akt protein kinase inhibitors |
| JP5213229B2 (ja) | 2004-04-23 | 2013-06-19 | エグゼリクシス， インコーポレイテッド | キナーゼ調節因子および使用方法 |
| WO2005113762A1 (en) | 2004-05-18 | 2005-12-01 | Pfizer Products Inc. | CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF |
| US20060025074A1 (en) | 2004-07-30 | 2006-02-02 | Chih-Ming Liang | Bluetooth-based headset |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| GB0419161D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| TWM266655U (en) | 2004-09-23 | 2005-06-01 | Blueexpert Technology Corp | Bluetooth earphone device capable of wirelessly receiving and transmitting stereo sound signal and digital information signal |
| TW200621257A (en) * | 2004-10-20 | 2006-07-01 | Astellas Pharma Inc | Pyrimidine derivative fused with nonaromatic ring |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| ATE543821T1 (de) | 2004-12-28 | 2012-02-15 | Exelixis Inc | Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen |
| CA2598956A1 (en) | 2005-02-24 | 2006-08-31 | Pfizer Products Inc. | Bicyclic heteroaromatic derivatives useful as anticancer agents |
| US20090029982A1 (en) * | 2005-04-28 | 2009-01-29 | Supergen, Inc. | Protein kinase inhibitors |
| EP1881983B1 (en) | 2005-05-20 | 2012-01-11 | Vertex Pharmaceuticals, Inc. | Pyrrolopyridines useful as inhibitors of protein kinase |
| HRP20130429T1 (en) | 2005-06-10 | 2013-06-30 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| UY29610A1 (es) | 2005-06-21 | 2007-01-31 | Cancer Rec Tech Ltd | Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica |
| EP1948659A1 (en) | 2005-10-13 | 2008-07-30 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as syk inhibitors |
| WO2007077961A2 (en) | 2005-12-28 | 2007-07-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands |
| JP2009534454A (ja) | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| KR20090024834A (ko) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| NZ573979A (en) | 2006-07-06 | 2012-02-24 | Array Biopharma Inc | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| CA2655675A1 (en) | 2006-07-06 | 2008-01-10 | Glaxo Group Limited | Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use |
| US8329701B2 (en) | 2006-07-06 | 2012-12-11 | Array Biopharma Inc. | Dihydrofuro pyrimidines as AKT protein kinase inhibitors |
| GB0613518D0 (en) | 2006-07-06 | 2006-08-16 | Phytopharm Plc | Chemical compounds |
| UA95641C2 (xx) | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008029907A1 (en) * | 2006-09-08 | 2008-03-13 | Kyowa Hakko Bio Co., Ltd. | Hypertension-ameliorating agent |
| US7741347B2 (en) * | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX2009014013A (es) | 2007-07-05 | 2010-01-28 | Array Biopharma Inc | Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt. |
| US8629171B2 (en) * | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| EP2240455B1 (en) | 2008-01-09 | 2012-12-26 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor |
| ES2426092T3 (es) | 2008-01-09 | 2013-10-21 | Array Biopharma, Inc. | 5H-Ciclopenta[d]pirimidinas como inhibidores de proteínas cinasas AKT |
| ES2422733T3 (es) | 2008-01-09 | 2013-09-13 | Array Biopharma Inc | Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT |
| US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7906655B2 (en) * | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2010096462A1 (en) * | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
| HUE036906T2 (hu) * | 2009-05-13 | 2018-08-28 | Antivirális vegyületek |
-
2008
- 2008-07-03 ES ES08781337.4T patent/ES2551352T3/es active Active
- 2008-07-03 BR BRPI0813999A patent/BRPI0813999A2/pt not_active Application Discontinuation
- 2008-07-03 AR ARP080102885A patent/AR067413A1/es unknown
- 2008-07-03 SG SG2012073854A patent/SG185274A1/en unknown
- 2008-07-03 KR KR1020157020046A patent/KR20150089099A/ko not_active Ceased
- 2008-07-03 CN CN201310128477.3A patent/CN103396409B/zh active Active
- 2008-07-03 RU RU2010103813/04A patent/RU2486181C2/ru active
- 2008-07-03 EP EP08781337.4A patent/EP2170863B1/en active Active
- 2008-07-03 TW TW097125055A patent/TWI450720B/zh not_active IP Right Cessation
- 2008-07-03 KR KR1020107002558A patent/KR101650956B1/ko not_active Expired - Fee Related
- 2008-07-03 WO PCT/US2008/069144 patent/WO2009006567A2/en not_active Ceased
- 2008-07-03 US US12/667,848 patent/US8618097B2/en active Active
- 2008-07-03 AU AU2008272830A patent/AU2008272830B8/en not_active Ceased
- 2008-07-03 NZ NZ582692A patent/NZ582692A/en not_active IP Right Cessation
- 2008-07-03 CN CN2008801058695A patent/CN101801955B/zh active Active
- 2008-07-03 JP JP2010515269A patent/JP5628028B2/ja active Active
- 2008-07-03 CA CA2692502A patent/CA2692502C/en not_active Expired - Fee Related
-
2010
- 2010-01-19 CR CR11229A patent/CR11229A/es unknown
- 2010-01-29 CO CO10009431A patent/CO6251283A2/es active IP Right Grant
- 2010-02-04 EC EC2010009937A patent/ECSP109937A/es unknown
- 2010-02-05 MA MA32596A patent/MA31679B1/fr unknown
-
2013
- 2013-10-02 JP JP2013207007A patent/JP2014028842A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067413A1 (es) | Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR060903A1 (es) | Derivados de 1,2,3,4-tetrahidro-quinolina como inhibidores de cetp | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| AR085489A1 (es) | Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias | |
| AR073406A1 (es) | Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer. | |
| AR085316A1 (es) | Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas | |
| AR070136A1 (es) | Pirimidil ciclopentanos como inhibidores de la akt proteina quinasa | |
| PE20190336A1 (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR078228A1 (es) | Inhibidores de cyp17 | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| PE20200388A1 (es) | Amidas heterociclicas de 5 miembros y biciclicas como inhibidores de rock | |
| PE20130188A1 (es) | Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk | |
| AR087591A1 (es) | Derivados de ciclohexil azetidina como inhibidores de jak | |
| AR075635A1 (es) | N-alcoxiamidas de 6-(fenil sustituido)-4-aminopicolinatos y 2-(fenil sustituido)-6-amino-4-pirimidina carboxilatos, su uso como herbicidas selectivos para las cosechas y proceso de preparacion de dichos compuestos | |
| EA201170099A1 (ru) | Замещенные пиримидин-4-оновые производные | |
| AR087288A1 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| AR078786A1 (es) | Derivados de la cromenona | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |